Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
6.02
+0.02 (0.33%)
At close: Dec 5, 2025, 4:00 PM EST
6.02
0.00 (0.00%)
After-hours: Dec 5, 2025, 6:43 PM EST
Coya Therapeutics Revenue
Coya Therapeutics had revenue of $3.56M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $3.99M, down -58.26% year-over-year. In the year 2024, Coya Therapeutics had annual revenue of $3.55M, down -40.79%.
Revenue (ttm)
$3.99M
Revenue Growth
-58.26%
P/S Ratio
25.11
Revenue / Employee
$498,463
Employees
8
Market Cap
125.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
| Dec 31, 2023 | 6.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
COYA News
- 10 days ago - Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences - Business Wire
- 23 days ago - Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update - Business Wire
- 4 weeks ago - Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo - Business Wire
- 5 weeks ago - Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares - Business Wire
- 6 weeks ago - Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock - Business Wire
- 6 weeks ago - Coya Therapeutics Announces Proposed Public Offering of Common Stock - Business Wire
- 2 months ago - Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function - Business Wire
- 2 months ago - Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia - PRNewsWire